Treatment patterns and cost of care associated with initial therapy among patients diagnosed with operable early-stage human epidermal growth factor receptor 2-overexpressed breast cancer in the United States: A real-world retrospective study

Journal of Oncology Practice

Volumn 12, Issue 2, 2016, Pages 161-167

  Byfield, Stacey Dacosta ^a   Buck, Philip O ^b   Blauer Peterson, Cori ^b   Poston, Sara A ^b  

^a OPTUM   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIANEMIC AGENT; ANTIEMETIC AGENT; CARBOPLATIN; COLONY STIMULATING FACTOR 1; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HORMONE RECEPTOR; LAPATINIB; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; EARLY CANCER; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NAUSEA AND VOMITING; NEUTROPENIA; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; UNITED STATES; AGED; BREAST NEOPLASMS; CLINICAL PRACTICE; FACTUAL DATABASE; GENE EXPRESSION; GENETICS; TIME FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DATABASES, FACTUAL; FEMALE; GENE EXPRESSION; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PRACTICE PATTERNS, PHYSICIANS'; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES;

EID: 84958240098     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2015.004747     Document Type: Article

References (22)

1. Siegel R, Ma J, Zou Z, et al: Cancer statistics, 2014. CA Cancer J Clin 64:9-29, 2014
2. Seshadri R, Firgaira FA, Horsfall DJ, et al: Clinical significance of HER-2/neu oncogene amplification in primary breast cancer: The South Australian Breast Cancer Study Group. J Clin Oncol 11:1936-1942, 1993
3. Genentech: Trastuzumab product information. www.accessdata.fda.gov/drug-satfda-docs/label/2010/103792s5250lbl.pdf
4. Novartis: Pertuzumab product information. www.pharma.us.novartis.com/prod-uct/pi/pdf/tykerb.pdf
5. GlaxoSmithKline: Lapatinib product information. www.accessdata.fda.gov/drug-satfda-docs/label/2010/022059s3s6lbl.pdf
6. Genentech: Ado-trastuzumab emtansine product information. www.accessdata. fda.gov/drugsatfda-docs/label/2013/125427lbl.pdf
7. Montero AJ, Eapen S, Gorin B, et al: The economic burden of metastatic breast cancer: A U.S. managed care perspective. Breast Cancer Res Treat 134:815-822, 2012
8. Baffert S, Cottu P, Kirova YM, et al: Treatment patterns, clinical outcomes and health care costs associated with HER2-positive breast cancer with central nervous system metastases: A French multicentre observational study. BMC Health Serv Res 13:456, 2013
9. Metzger-Filho O, Sun Z, Viale G, et al: Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: Results from International Breast Cancer Study Group trials VIII and IX. J Clin Oncol 31: 3083-3090, 2013
10. Whyte J, Engel-Nitz N, Teitelbaum A, et al: An evaluation of algorithms for identifying metastatic breast, lung, or colorectal cancer in administrative claims data. Med Care 53:e49-e57, 2015
11. Stokes ME, Thompson D, Montoya EL, et al: Ten-year survival and cost following breast cancer recurrence: Estimates from SEER-medicare data. Value Health 11: 213-220, 2008
12. Lin DY, Feuer EJ, Etzioni R, et al: Estimating medical costs from incomplete follow-up data. Biometrics 53:419-434, 1997
13. Graubard BI, Korn EL: Predictive margins with survey data. Biometrics 55: 652-659, 1999
14. Lane PW, Nelder JA: Analysis of covariance and standardization as instances of prediction. Biometrics 38:613-621, 1982
15. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987
16. Howlader N, Altekruse SF, Li CI, et al: US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106:dju055, 2014
17. Montemurro F, Aglietta M: Hormone receptor-positive early breast cancer: Controversies in the use of adjuvant chemotherapy. Endocr Relat Cancer 16: 1091-1102, 2009
18. Noonan KL, McCarthy J, Powell E, et al: A population-based analysis of patients with early-stage HER2-positive breast cancer in Newfoundland and Labrador. Oncology Exchange 11:14-19, 2012. www.oncologyex.com/pdf/vol11-no4/research-her2-positive-breast-cancer.pdf
19. Zurawska U, Baribeau DA, Giilck S, et al: Outcomes of HER2-positive early-stage breast cancer in the trastuzumab era: A population-based study of Canadian patients. Curr Oncol 20:e539-e545, 2013
20. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immu-nohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795, 2010
21. Lin CM, Jaswal J, Vandenberg T, et al: Weakly hormone receptor-positive breast cancer and use of adjuvant hormonal therapy. Curr Oncol 20:e612-e613, 2013
22. Campbell JD, Ramsey SD: The costs of treating breast cancer in the US: A synthesis of published evidence. Pharmacoeconomics 27:199-209, 2009